Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O75096: Variant p.Asp529Asn

Low-density lipoprotein receptor-related protein 4
Gene: LRP4
Feedback?
Variant information Variant position: help 529 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Aspartate (D) to Asparagine (N) at position 529 (D529N, p.Asp529Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CLSS; abolishes the antagonistic effect of LRP4 on LRP6-mediated activation of Wnt signaling. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 529 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1905 The length of the canonical sequence.
Location on the sequence: help GLESPGGLAVDWVHDKLYWT D SGTSRIEVANLDGAHRKVLL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GLESPGGLAVDWVHDKLYWTDSGTSRIEVANLDGAHRKVLL

Mouse                         GLESPGGLAVDWVHDKLYWTDSGTSRIEVANLDGAHRKVLL

Rat                           GLESPGGLAVDWVHDKLYWTDSGTSRIEVANLDGAHRKVLL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 21 – 1905 Low-density lipoprotein receptor-related protein 4
Topological domain 21 – 1725 Extracellular
Repeat 523 – 565 LDL-receptor class B 2



Literature citations
LRP4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome.
Li Y.; Pawlik B.; Elcioglu N.; Aglan M.; Kayserili H.; Yigit G.; Percin F.; Goodman F.; Nurnberg G.; Cenani A.; Urquhart J.; Chung B.D.; Ismail S.; Amr K.; Aslanger A.D.; Becker C.; Netzer C.; Scambler P.; Eyaid W.; Hamamy H.; Clayton-Smith J.; Hennekam R.; Nurnberg P.; Herz J.; Temtamy S.A.; Wollnik B.;
Am. J. Hum. Genet. 86:696-706(2010)
Cited for: FUNCTION IN THE REGULATION OF CANONICAL WTN SIGNALING; VARIANTS CLSS ASN-137; TYR-160; ASN-449; PRO-461; PHE-473; ASN-529 AND ARG-1017; CHARACTERIZATION OF VARIANTS CLSS ASN-137; TYR-160; ASN-449; PHE-473 AND ASN-529;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.